Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP
Two Federal Circuit judges did not seem fully convinced Friday that three Stanford University patents licensed to CareDx Inc., developer of commercial tests for kidney transplant rejections, are valid under the...To view the full article, register now.
Already a subscriber? Click here to view full article